Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13095827 | 0.83 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3HSD17B10USP2 | |
| SCHEMBL59810 | 0.83 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3HSD17B10USP2 | |
| SCHEMBL4854900 | 0.83 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3HSD17B10USP2 | |
| SCHEMBL5289317 | 0.83 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3HSD17B10USP2 | |
| SCHEMBL1539194 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10PKM | |
| SCHEMBL1065163 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10USP2 | |
| SCHEMBL5279998 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10USP2 | |
| SCHEMBL5292853 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10PKM | |
| SCHEMBL15349978 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10USP2 | |
| SCHEMBL11164475 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891176-B1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2024-06-05 | — | — | EP | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| CN-107205948-B | Tablets comprising a GLP-1 agonist and an enteric coating | 诺和诺德股份有限公司 | 2021-12-14 | — | — | CN | claimed |
| US-11117947-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-09-14 | — | — | US | claimed |
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | claimed |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-06-15 | — | — | US | claimed |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2020-09-17 | — | — | US | claimed |
| EP-1049486-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 2000-11-08 | — | — | EP | claimed |
| US-5981488-A | POLYPEPTIDE; ANTIDIABETIC AGENT | ELI LILLLY AND COMPANY (US) | 1999-11-09 | — | — | US | claimed |
| US-5977071-A | COMPLEXES; ANTIDIABETIC AGENT | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | claimed |
| WO-1999029336-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | claimed |
| EP-0869135-A1 | Glucagon-like peptide-1 analogs | ELI LILLY AND COMPANY (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0733644-A1 | Glucagon-like insulinotropic complexes, compositions and methods | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
| US-5371234-A | Ion specific chelating agents derived from β-hydroxyhistidine, 4-(1-hydroxy-1-alkyl)imidazole and derivatives thereof | THE UNITES STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF COMMERCE (US) | 1994-12-06 | — | — | US | claimed |
| US-RE30413-E | ANTIBIOTICS; ANTITUMOR AGENTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-10-07 | — | — | US | claimed |
| US-4051237-A | FROM STREPTOALLOTEICHUS HINDUSTANUS | BRISTOL-MYERS COMPANY (US) | 1977-09-27 | — | — | US | claimed |
| US-3932374-A | ANTITUMOR AGENTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117947-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | SLC7A5 491/4885CYP3A4 3228/4885SLC1A3 667/4885 |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | SLC7A5 484/4885CYP3A4 3228/4885SLC1A3 663/4885 |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | SLC7A5 764/4885CYP3A4 27/4885SLC1A3 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.